Salidroside inhibits insulin resistance and hepatic steatosis by downregulating miR-21 and subsequent activation of AMPK and upregulation of PPARα in the liver and muscles of high fat diet-fed rats

References

• Ahn, J., et al., 2012. Lycopene inhibits hepatic steatosis via microRNA-21-induced downregulation of fatty acid-binding protein 7 in mice fed a high-fat diet. Molecular nutrition & food research, 56 (11), 1665–1674.
   PubMed Web of Science ®Google Scholar
• Bellentani, S., et al., 2010. Epidemiology of non-alcoholic fatty liver disease. Digestive diseases (Basel, Switzerland), 28 (1), 155–161.
   PubMed Web of Science ®Google Scholar
• Benhamouche-Trouillet, S. and Postic, C., 2016. Emerging role of miR-21 in non-alcoholic fatty liver disease. Gut, 65 (11), 1781–1783.
   PubMed Web of Science ®Google Scholar
• Bladé, C., et al., 2013. miRNAs, polyphenols, and chronic disease. Molecular nutrition & food research, 57 (1), 58–70.
   PubMed Web of Science ®Google Scholar
• Bougarne, N., et al., 2018. Molecular actions of PPARα in lipid metabolism and inflammation. Endocrine reviews, 39 (5), 760–802.
   PubMed Web of Science ®Google Scholar
• Boyer-Diaz, Z., et al., 2021. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. Journal of hepatology, 74 (5), 1188–1199.
   PubMed Web of Science ®Google Scholar
• Buzzetti, E., Pinzani, M., and Tsochatzis, E.A., 2016. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism: clinical and experimental, 65 (8), 1038–1048.
   PubMed Web of Science ®Google Scholar
• Calo, N., et al., 2016. Stress-activated miR-21/miR-21* in hepatocytes promotes lipid and glucose metabolic disorders associated with high-fat diet consumption. Gut, 65 (11), 1871–1881.
   PubMed Web of Science ®Google Scholar
• Chambel, S.S., Santos-Gonçalves, A., and Duarte, T.L., 2015. The dual role of Nrf2 in nonalcoholic fatty liver disease: regulation of antioxidant defenses and hepatic lipid metabolism. BioMed research international, 2015, 597134.
   PubMed Web of Science ®Google Scholar
• Chanda, D., et al., 2009. Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner. Hepatology (Baltimore, MD), 50 (3), 880–892.
   PubMed Web of Science ®Google Scholar
• Chen, Q., Lu, X., and Zhang, X., 2021. Noncanonical NF-κB signaling pathway in liver diseases. Journal of clinical and translational hepatology, 9 (1), 81–89.
   PubMed Web of Science ®Google Scholar
• Chen, Q., et al., 2017. Pathogenic role of microRNA-21 in diabetic retinopathy through downregulation of PPARα. Diabetes, 66 (6), 1671–1682.
   PubMed Web of Science ®Google Scholar
• Cheng, C.F., Chen, H.H., and Lin, H., 2010. Role of PPARα and its agonist in renal diseases. PPAR research, 2010, 345098.
   PubMedGoogle Scholar
• Chuppa, S., et al., 2018. MicroRNA-21 regulates peroxisome proliferator-activated receptor alpha, a molecular mechanism of cardiac pathology in Cardiorenal Syndrome Type 4. Kidney international, 93 (2), 375–389.
   PubMed Web of Science ®Google Scholar
• Cobbina, E. and Akhlaghi, F., 2017. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug metabolism reviews, 49 (2), 197–211.
   PubMed Web of Science ®Google Scholar
• Dattaroy, D., et al., 2015. Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis. American journal of physiology gastrointestinal and liver physiology, 308 (4), G298–312.
   PubMed Web of Science ®Google Scholar
• Day, E.A., Ford, R.J., and Steinberg, G.R., 2017. AMPK as a therapeutic target for treating metabolic diseases. Trends in endocrinology and metabolism, 28 (8), 545–560.
   PubMed Web of Science ®Google Scholar
• Ding, S., et al., 2017. Resveratrol and caloric restriction prevent hepatic steatosis by regulating SIRT1-autophagy pathway and alleviating endoplasmic reticulum stress in high-fat diet-fed rats. PLoS one, 12 (8), e0183541.
   PubMed Web of Science ®Google Scholar
• Dongiovanni, P., et al., 2018. miRNA Signature in NAFLD: a turning point for a non-invasive diagnosis. International journal of molecular sciences, 19 (12), 3966.
   PubMed Web of Science ®Google Scholar
• Fan, F., et al., 2020. Salidroside as a potential neuroprotective agent for ischemic stroke: a review of sources, pharmacokinetics, mechanism and safety. Biomedicine & pharmacotherapy, 129, 110458.
   PubMed Web of Science ®Google Scholar
• Feng, Q., et al., 2019. Salidroside-mitigated inflammatory injury of hepatocytes with non-alcoholic fatty liver disease via inhibition TRPM2 ion channel activation. Diabetes, metabolic syndrome and obesity, 12, 2755–2763.
   PubMed Web of Science ®Google Scholar
• Folch, J., Lees, M., and Sloane Stanley, G.H., 1957. A simple method for the isolation and purification of total lipides from animal tissues. The journal of biological chemistry, 226 (1), 497–509.
   PubMed Web of Science ®Google Scholar
• Foretz, M., et al., 1999. ADD1/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose. Molecular and cellular biology, 19 (5), 3760–3768.
   PubMed Web of Science ®Google Scholar
• Gao, Z. and Li, Y.H., 2012. Antioxidant stress and anti-inflammation of PPARα on warm hepatic Ischemia-reperfusion injury. PPAR research, 2012, 738785.
   PubMed Web of Science ®Google Scholar
• Hao, Y., et al., 2021. Formononetin protects against cisplatin‑induced acute kidney injury through activation of the PPARα/Nrf2/HO‑1/NQO1 pathway. International journal of molecular medicine, 47 (2), 511–522.
   PubMed Web of Science ®Google Scholar
• Hasanvand, A., et al., 2016. Anti-inflammatory effect of AMPK signaling pathway in rat model of diabetic neuropathy. Inflammopharmacology, 24 (5), 207–219.
   PubMed Web of Science ®Google Scholar
• Hu, M., et al., 2021. Salidroside activates the AMP-activated protein kinase pathway to suppress non-alcoholic steatohepatitis. Hepatology, 74 (6), 3056–3073.
   PubMed Web of Science ®Google Scholar
• Jiang, G., et al., 2020. Effects of wogonoside on the inflammatory response and oxidative stress in mice with nonalcoholic fatty liver disease. Pharmaceutical biology, 58 (1), 1177–1183.
   PubMed Web of Science ®Google Scholar
• Kida, K., et al., 2011. PPARα is regulated by miR-21 and miR-27b in human liver. Pharmaceutical research, 28 (10), 2467–2476.
   PubMed Web of Science ®Google Scholar
• Klieser, E., et al., 2019. The crosstalk of miRNA and oxidative stress in the liver: from physiology to pathology and clinical implications. International journal of molecular sciences, 20 (21), 5266.
   PubMed Web of Science ®Google Scholar
• Kondo, Y., et al., 2013. PPARs and liver disease. PPAR research, 2013, 896412.
   PubMed Web of Science ®Google Scholar
• Kosakowska, O., et al., 2018. Antioxidant and antibacterial activity of roseroot (Rhodiola rosea L.) dry extracts. Molecules, 23 (7), 1767.
   PubMed Web of Science ®Google Scholar
• Kusnadi, A., et al., 2019. The Cytokine TNF promotes transcription factor SREBP activity and binding to inflammatory genes to activate macrophages and limit tissue repair. Immunity, 51 (2), 241–257.e249.
   PubMed Web of Science ®Google Scholar
• Lee, W.H. and Kim, S.G., 2010. AMPK-dependent metabolic regulation by PPAR agonists. PPAR research, 2010, 1–10.
   Web of Science ®Google Scholar
• Li, H., et al., 2017. Salidroside modulates insulin signaling in a rat model of nonalcoholic steatohepatitis. Evidence-based complementary and alternative medicine, 2017, 1–6.
   Web of Science ®Google Scholar
• Li, H.S., 2018. Salidroside and curcumin formula prevents liver injury in nonalcoholic fatty liver disease in rats. Annals of hepatology, 17 (5), 769–778.
   PubMed Web of Science ®Google Scholar
• Li, S., et al., 2020. Activation of the AMPK-SIRT1 pathway contributes to protective effects of Salvianolic acid A against lipotoxicity in hepatocytes and NAFLD in mice. Frontiers in pharmacology, 11, 560905.
   PubMed Web of Science ®Google Scholar
• Liangpunsakul, S., et al., 2009. Effects of WY-14,643 on the phosphorylation and activation of AMP-dependent protein kinase. Archives of biochemistry and biophysics, 485 (1), 10–15.
   PubMed Web of Science ®Google Scholar
• Liu, B., et al., 2020. MicroRNA-21 mediates the protective effects of salidroside against hypoxia/reoxygenation-induced myocardial oxidative stress and inflammatory response. Experimental and therapeutic medicine, 19 (3), 1655–1664.
   PubMed Web of Science ®Google Scholar
• López-Sánchez, G.N., et al., 2021. Non-alcoholic fatty liver disease and microRNAs expression, how it affects the development and progression of the disease. Annals of hepatology, 21, 100212.
   PubMed Web of Science ®Google Scholar
• Loyer, X., et al., 2016. Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression. Gut, 65 (11), 1882–1894.
   PubMed Web of Science ®Google Scholar
• Luci, C., et al., 2020. Chronic inflammation in non-alcoholic steatohepatitis: molecular mechanisms and therapeutic strategies. Frontiers in endocrinology (Lausanne), 11, 597648.
   PubMed Web of Science ®Google Scholar
• Masarone, M., et al., 2018. Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease. Oxidative medicine and cellular longevity, 2018, 1–14.
   Web of Science ®Google Scholar
• Mehta, S.R., 2010. Advances in the treatment of nonalcoholic fatty liver disease. Therapeutic advances in endocrinology and metabolism, 1 (3), 101–115.
   PubMedGoogle Scholar
• Meng, F., et al., 2007. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 133 (2), 647–658.
   PubMed Web of Science ®Google Scholar
• Miranda, D.A., et al., 2018. LRH-1 regulates hepatic lipid homeostasis and maintains arachidonoyl phospholipid pools critical for phospholipid diversity. JCI insight, 3 (5), e96151.
   PubMed Web of Science ®Google Scholar
• Mo, C., et al., 2014. The crosstalk between Nrf2 and AMPK signal pathways is important for the anti-inflammatory effect of berberine in LPS-stimulated macrophages and endotoxin-shocked mice. Antioxidants & redox signaling, 20 (4), 574–588.
   PubMed Web of Science ®Google Scholar
• Morgan, M.J. and Liu, Z.G., 2011. Crosstalk of reactive oxygen species and NF-κB signaling. Cell research, 21 (1), 103–115.
   PubMed Web of Science ®Google Scholar
• Moslehi, A. and Hamidi-Zad, Z., 2018. Role of SREBPs in liver diseases: a mini-review. Journal of clinical and translational hepatology, 6 (3), 332–338.
   PubMed Web of Science ®Google Scholar
• O’Neill, H.M., 2013. AMPK and exercise: glucose uptake and insulin sensitivity. Diabetes & metabolism journal, 37 (1), 1–21.
   PubMedGoogle Scholar
• Pawlak, M., et al., 2015a. Ketone body therapy protects from lipotoxicity and acute liver failure upon Pparα deficiency. Molecular endocrinology (Baltimore, MD), 29 (8), 1134–1143.
   PubMedGoogle Scholar
• Pawlak, M., Lefebvre, P., and Staels, B., 2015b. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. Journal of hepatology, 62 (3), 720–733.
   PubMed Web of Science ®Google Scholar
• Peyrou, M., et al., 2012. PPARs in liver diseases and cancer: epigenetic regulation by MicroRNAs. PPAR research, 2012, 757803.
   PubMed Web of Science ®Google Scholar
• Pomari, E., Stefanon, B., and Colitti, M., 2015. Effects of two different Rhodiola rosea extracts on primary human visceral adipocytes. Molecules (Basel, Switzerland), 20 (5), 8409–8428.
   PubMed Web of Science ®Google Scholar
• Pulito, C., et al., 2017. Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities. Cell discovery, 3, 17022.
   PubMed Web of Science ®Google Scholar
• Régnier, M., et al., 2020. Hepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity. Scientific reports, 10 (1), 6489.
   PubMed Web of Science ®Google Scholar
• Rodrigues, P.M., et al., 2017. miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice. Cell death & disease, 8 (4), e2748.
   PubMedGoogle Scholar
• Rolo, A.P., Teodoro, J.S., and Palmeira, C.M., 2012. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free radical biology and medicine, 52 (1), 59–69.
   PubMed Web of Science ®Google Scholar
• Roza, N.A., et al., 2016. Effect of long-term high-fat diet intake on peripheral insulin sensibility, blood pressure, and renal function in female rats. Food & nutrition research, 60 (1), 28536.
   PubMed Web of Science ®Google Scholar
• Sekiya, M., et al., 2008. Oxidative stress induced lipid accumulation via SREBP1c activation in HepG2 cells. Biochemical and biophysical research communications, 375 (4), 602–607.
   PubMed Web of Science ®Google Scholar
• Seo, Y.S., et al., 2008. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. Journal of gastroenterology and hepatology, 23 (1), 102–109.
   PubMed Web of Science ®Google Scholar
• Smith, B.K., et al., 2016. Treatment of nonalcoholic fatty liver disease: role of AMPK. American journal of physiology endocrinology and metabolism, 311 (4), E730–e740.
   PubMed Web of Science ®Google Scholar
• Souza-Mello, V., 2015. Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease. World journal of hepatology, 7 (8), 1012–1019.
   PubMed Web of Science ®Google Scholar
• Stebbins, K.J., et al., 2017. In vitro and in vivo pharmacology of NXT629, a novel and selective PPARα antagonist. European journal of pharmacology, 809, 130–140.
   PubMed Web of Science ®Google Scholar
• Sun, C., Fan, J.G., and Qiao, L., 2015. Potential epigenetic mechanism in non-alcoholic Fatty liver disease. International journal of molecular sciences, 16 (3), 5161–5179.
   PubMed Web of Science ®Google Scholar
• Tong, Y., et al., 2016. Functional genetic variants of PPARx03B3; and PPARα encoding peroxisome proliferator-activated receptors and susceptibility to ischemic stroke in Chinese Han population. Cerebrovascular diseases (Basel, Switzerland), 41 (1–2), 96–99.
   PubMed Web of Science ®Google Scholar
• Van De Wier, B., et al., 2017. The potential of flavonoids in the treatment of non-alcoholic fatty liver disease. Critical reviews in food science and nutrition, 57 (4), 834–855.
   PubMed Web of Science ®Google Scholar
• Vancells Lujan, P., Viñas Esmel, E., and Sacanella Meseguer, E., 2021. Overview of non-alcoholic fatty liver disease (NAFLD) and the role of sugary food consumption and other dietary components in its development. Nutrients, 13 (5), 1442.
   PubMed Web of Science ®Google Scholar
• Vinciguerra, M., et al., 2009. Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology (Baltimore, MD), 49 (4), 1176–1184.
   PubMed Web of Science ®Google Scholar
• Wang, X., et al., 2021. MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut, 70 (4), 784–795.
   PubMed Web of Science ®Google Scholar
• Wang, X.M., et al., 2019. Role and mechanisms of action of microRNA‑21 as regards the regulation of the WNT/β‑catenin signaling pathway in the pathogenesis of non‑alcoholic fatty liver disease. International journal of molecular medicine, 44 (6), 2201–2212.
   PubMedGoogle Scholar
• Wang, Y., et al., 2020. PPARs as metabolic regulators in the liver: lessons from liver-specific PPAR-null mice. International journal of molecular sciences, 21 (6), 2061.
   PubMed Web of Science ®Google Scholar
• Wardyn, J.D., Ponsford, A.H., and Sanderson, C.M., 2015. Dissecting molecular cross-talk between Nrf2 and NF-κB response pathways. Biochemical society transactions, 43 (4), 621–626.
   PubMed Web of Science ®Google Scholar
• Wei, J., et al., 2013. MicroRNA-21 activates hepatic stellate cells via PTEN/Akt signaling. Biomedicine & pharmacotherapy = biomedecine & pharmacotherapie, 67 (5), 387–392.
   PubMed Web of Science ®Google Scholar
• Wu, H., et al., 2016. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway. Gut, 65 (11), 1850–1860.
   PubMed Web of Science ®Google Scholar
• Xiong, Y., et al., 2021. Protective effect of Salidroside on hypoxiarelated liver oxidative stress and inflammation via Nrf2 and JAK2/STAT3 signaling pathways. Food science & nutrition, 9 (9), 5060–5069.
   PubMed Web of Science ®Google Scholar
• Yang, Z.R., et al., 2016. Salidroside alleviates oxidative stress in the liver with non- alcoholic steatohepatitis in rats. BMC pharmacology & toxicology, 17, 16.
   PubMed Web of Science ®Google Scholar
• Yu, J., et al., 2016. The pathogenesis of nonalcoholic fatty liver disease: interplay between diet, gut microbiota, and genetic background. Gastroenterology research and practice, 2016, 2862173.
   PubMed Web of Science ®Google Scholar
• Yuan, Y., et al., 2019. Ameliorative effect of salidroside from Rhodiola Rosea L. on the gut microbiota subject to furan-induced liver injury in a mouse model. Food and chemical toxicology, 125, 333–340.
   PubMed Web of Science ®Google Scholar
• Zeng, L., et al., 2014. Signal transductions and nonalcoholic fatty liver: a mini-review. International journal of clinical and experimental medicine, 7 (7), 1624–1631.
   PubMed Web of Science ®Google Scholar
• Zeng, T., et al., 2016. Blocking nuclear factor-kappa B protects against diet-induced hepatic steatosis and insulin resistance in mice. PLoS One, 11 (3), e0149677.
   PubMed Web of Science ®Google Scholar
• Zhang, T., et al., 2020a. Critical role of microRNA-21 in the pathogenesis of liver diseases. Frontiers in medicine (Lausanne), 7, 7.
   PubMed Web of Science ®Google Scholar
• Zhang, X., et al., 2020b. Salidroside protects mice against CCl4-induced acute liver injury via down-regulating CYP2E1 expression and inhibiting NLRP3 inflammasome activation. International immunopharmacology, 85, 106662.
   PubMed Web of Science ®Google Scholar
• Zhang, X.R., et al., 2016. Salidroside-regulated lipid metabolism with down-regulation of miR-370 in type 2 diabetic mice. European journal of pharmacology, 779, 46–52.
   PubMed Web of Science ®Google Scholar
• Zhao, C.C., et al., 2021. The therapeutic effects and mechanisms of salidroside on cardiovascular and metabolic diseases: an updated review. Chemistry & biodiversity, 18 (7), e2100033.
   PubMed Web of Science ®Google Scholar
• Zheng, L., et al., 2020. Salidroside regulates inflammatory pathway of alveolar macrophages by influencing the secretion of miRNA-146a exosomes by lung epithelial cells. Scientific reports, 10 (1), 20750.
   PubMed Web of Science ®Google Scholar
• Zheng, T., et al., 2018. Salidroside attenuates high-fat diet-induced nonalcoholic fatty liver disease via AMPK-dependent TXNIP/NLRP3 pathway. Oxidative medicine and cellular longevity, 2018, 8597897.
   PubMed Web of Science ®Google Scholar
• Zhong, Z., et al., 2018. Pharmacological activities, mechanisms of action, and safety of salidroside in the central nervous system. Drug design, development and therapy, 12, 1479–1489.
   PubMed Web of Science ®Google Scholar
• Zhou, J., et al., 2011. MicroRNA-21 targets peroxisome proliferators-activated receptor-alpha in an autoregulatory loop to modulate flow-induced endothelial inflammation. Proceedings of the national academy of sciences of the United States of America, 108 (25), 10355–10360.
   PubMed Web of Science ®Google Scholar
• Zimmermann, K., et al., 2015. Activated AMPK boosts the Nrf2/HO-1 signaling axis-A role for the unfolded protein response. Free radical biology & medicine, 88 (Pt B), 417–426.
   PubMedGoogle Scholar